Document Detail

Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
MedLine Citation:
PMID:  19755624     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To compile evidence from randomized controlled trials, case series, and case reports to identify the effectiveness of various therapeutic agents for the treatment and prevention of dermatologic effects secondary to epidermal growth factor receptor inhibitor (EGFRI) administration. DATA SOURCES: Literature was accessed through PubMed (2002-May 2009) and Scopus (2002-March 2009), using the terms epidermal growth factor receptor inhibitor, cetuximab, erlotinib, gefitinib, panitumumab, management, skin toxicity, and cutaneous effects. In addition, reference citations from publications identified were reviewed. STUDY SELECTION AND DATA EXTRACTION: An evaluation of published clinical trials, case series, case reports, and clinical management guidelines that studied the treatment options for EGFRI-induced skin toxicities was performed. Studies that reported dosing regimens and treatment outcomes were included in this review. DATA SYNTHESIS: Management of EGFRI-induced skin toxicities has been documented in 2 randomized controlled trials, 3 case series, and 10 case reports in a total of 156 patients. There is strong evidence for the use of topical antibiotics to manage EGFRI skin toxicities. Controversy exists regarding the use of corticosteroids and retinoids for the management of EGFRI-induced rash. Several variables are noted among the number of case series and case reports, such as follow-up duration of the intervention, making any comparisons difficult. CONCLUSIONS: Overall, antibiotics are the most common treatment option and have the potential to reduce the severity of skin rash. Well-designed clinical studies with proper recording of relevant data on the management of EGFRI-induced dermatologic effects are needed to properly evaluate the use of various therapeutic agents. Apart from randomized controlled trials, comprehensive case reports are also important for clinical evaluation on a case-by-case basis.
Eng Hooi Tan; Alexandre Chan
Related Documents :
23955424 - Markers for nutrition studies: review of criteria for the evaluation of markers.
12741654 - Cannabis and violent crime.
20685164 - Immediate versus delayed self-reporting of symptoms and side effects during chemotherap...
23714974 - Pseudomeningocele presenting as a cyst of the external auditory canal.
942324 - Homograft tympanic membrane myringoplasty.
7234394 - Ultrasonography in the diagnosis of neonatal adrenal haemorrhage.
Publication Detail:
Type:  Journal Article; Review     Date:  2009-09-15
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  43     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-09-28     Completed Date:  2009-12-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1658-66     Citation Subset:  IM    
Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Cutaneous
Anti-Bacterial Agents / administration & dosage,  therapeutic use
Antineoplastic Agents / adverse effects*,  therapeutic use
Clinical Trials as Topic
Drug Eruptions / drug therapy*,  etiology
Evidence-Based Medicine
Neoplasms / drug therapy
Receptor, Epidermal Growth Factor / antagonists & inhibitors*
Severity of Illness Index
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Antineoplastic Agents; EC, Epidermal Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Morphine-induced muscle rigidity in a term neonate.
Next Document:  Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor...